These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 26233569)

  • 41. Emergent reversal of vitamin K antagonists: addressing all the factors.
    Martin DT; Barton CA; Dodgion C; Schreiber M
    Am J Surg; 2016 May; 211(5):919-25. PubMed ID: 27046797
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals.
    Santibanez M; Lesch CA; Lin L; Berger K
    J Crit Care; 2018 Dec; 48():183-190. PubMed ID: 30218958
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.
    Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM
    Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants?
    Mangram A; Oguntodu OF; Dzandu JK; Hollingworth AK; Hall S; Cung C; Rodriguez J; Yusupov I; Barletta JF
    J Crit Care; 2016 Jun; 33():252-6. PubMed ID: 27021851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
    Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
    Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjusted versus actual body weight dosing of 4-factor prothrombin complex concentrate in obese patients with warfarin-associated major bleeding.
    Smetana KS; Ziemba R; May CC; Erdman MJ; Van Matre ET; Jones GM
    J Thromb Thrombolysis; 2019 Apr; 47(3):369-374. PubMed ID: 30460443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of Temporary Warfarin Reversal in Patients With Left Ventricular Assist Devices: the KVAD Study.
    Sylvester KW; Grandoni J; Rhoten M; Coakley L; Lyons-Matiello E; Frankel K; Fortin B; Jolley K; Park HS; Freedman RY; Mehra MR; Givertz MM; Connors JM
    J Card Fail; 2024 Sep; 30(9):1111-1119. PubMed ID: 38521486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Experience on using prothrombin complex concentrate in urgent warfarin reversal: an Iranian survey.
    Haghpanah S; Karimi M; Bordbar M; Kamfiroozi R; Asgharzadeh H
    Clin Appl Thromb Hemost; 2013 Jun; 19(3):277-81. PubMed ID: 22734101
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage.
    Frontera JA; Gordon E; Zach V; Jovine M; Uchino K; Hussain MS; Aledort L
    Neurocrit Care; 2014 Dec; 21(3):397-406. PubMed ID: 24671832
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices.
    Rimsans J; Levesque A; Lyons E; Sylvester K; Givertz MM; Mehra MR; Stewart GC; Connors JM
    J Thromb Thrombolysis; 2018 Aug; 46(2):180-185. PubMed ID: 29785470
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dosing of 3-factor prothrombin complex concentrate for international normalized ratio reversal.
    Baggs JH; Patanwala AE; Williams EM; Erstad BL
    Ann Pharmacother; 2012 Jan; 46(1):51-6. PubMed ID: 22190253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding.
    Holt T; Taylor S; Abraham P; Mcmillian W; Harris S; Curtis J; Elder T
    Int J Crit Illn Inj Sci; 2018; 8(1):36-40. PubMed ID: 29619338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prothrombin complex concentrate for the urgent reversal of warfarin. Assessment of a standard dosing protocol.
    Wozniak M; Kruit A; Padmore R; Giulivi A; Bormanis J
    Transfus Apher Sci; 2012 Jun; 46(3):309-14. PubMed ID: 22503307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prothrombin complex concentrate (PCC, Octaplex) in patients requiring immediate reversal of vitamin K antagonist anticoagulation.
    Song MM; Warne CP; Crowther MA
    Thromb Res; 2012 Apr; 129(4):526-9. PubMed ID: 22304928
    [No Abstract]   [Full Text] [Related]  

  • 55. Comparison of 3 Different Prothrombin Complex Concentrate Regimens for Emergent Warfarin Reversal: PCCWaR Study.
    Dietrich SK; Rowe S; Cocchio CA; Harmon AJ; Nerenberg SF; Blankenship PS
    Ann Pharmacother; 2021 Aug; 55(8):980-987. PubMed ID: 33305592
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reversal of Warfarin-Associated Major Hemorrhage: Activated Prothrombin Complex Concentrate versus 4-Factor Prothrombin Complex Concentrate.
    Peksa GD; Mokszycki RK; Rech MA; Maynard B; Panos NG; Sweis RT; DeMott JM
    Thromb Haemost; 2020 Feb; 120(2):207-215. PubMed ID: 31837652
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
    Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
    Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Obesity increases risk of anticoagulation reversal failure with prothrombin complex concentrate in those with intracranial hemorrhage.
    Chu C; Tokumaru S; Izumi K; Nakagawa K
    Int J Neurosci; 2016; 126(1):62-6. PubMed ID: 25430740
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protocolized use of Factor Eight Inhibitor Bypassing Activity (FEIBA) for the reversal of warfarin induced coagulopathy.
    Htet NN; Barounis D; Knight C; Umunna BP; Hormese M; Lovell E
    Am J Emerg Med; 2020 Mar; 38(3):539-544. PubMed ID: 31176578
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Off-label use of 4-factor prothrombin complex concentrate is common despite little known benefit: A retrospective study.
    Scharman CD; Shatzel JJ; Kim E; DeLoughery TG
    Eur J Haematol; 2018 Sep; 101(3):349-353. PubMed ID: 29862565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.